stockrowGRAIL, Inc. (GRAL) vs QIAGEN N.V. (QGEN)
- GRAIL, Inc. GRAL 124.40 −13.41%
- QIAGEN N.V. QGEN 50.88 +0.10%
GRAIL, Inc. and QIAGEN N.V. are both Diagnostics & Research companies. QIAGEN N.V. is the larger, with a market value of $10.5B against $5.3B — 2.0× the size. GRAIL, Inc. has negative trailing earnings, so its P/E is not meaningful; QIAGEN N.V. trades at 26.1×. GRAIL, Inc. grew revenue faster over the last twelve months: 17.5% against 2.96%. QIAGEN N.V. has the higher net margin (19.5% vs −243.8%) and the higher return on invested capital (6.62% vs −14.7%). Across the 17 metrics below, QIAGEN N.V. leads on 13 and GRAIL, Inc. on 4.
Valuation
Profitability
| Metric | GRAL | QGEN | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 0.00% | 62.20% | 48.32% |
| Operating margin | (347.28%) | 21.21% | (5.68%) |
| Net margin | (243.80%) | 19.49% | (4.10%) |
| Free cash flow margin | (187.27%) | 20.98% | 0.00% |
| Return on equity | (17.31%) | 11.93% | 0.00% |
| Return on assets | (15.24%) | 6.99% | (6.05%) |
| Return on invested capital | (14.74%) | 6.62% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack